Vandetanib (ZD6474) , ≥99% , 443913-73-3
CAS NO.:443913-73-3
Empirical Formula: C22H24BrFN4O2
Molecular Weight: 475.35
MDL number: MFCD07772346
EINECS: 669-841-4
Pack Size | Price | Stock | Quantity |
25MG | RMB239.20 | In Stock |
|
100MG | RMB429.60 | In Stock |
|
500MG | RMB1208.80 | In Stock |
|
others | Enquire |
PRODUCT Properties
Melting point: | 240-2430C |
Boiling point: | 538.2±50.0 °C(Predicted) |
Density | 1.406 |
Flash point: | 279.3℃ |
storage temp. | Keep in dark place,Inert atmosphere,Store in freezer, under -20°C |
solubility | Soluble in DMSO (30 mg/ml); Ethanol (10 mg/ml with warming) |
pka | 8.92±0.10(Predicted) |
form | solid |
color | White to off-white |
Stability: | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 1 month. |
InChIKey | UHTHHESEBZOYNR-UHFFFAOYSA-N |
SMILES | N1=C2C(C=C(OC)C(OCC3CCN(C)CC3)=C2)=C(NC2=CC=C(Br)C=C2F)N=C1 |
CAS DataBase Reference | 443913-73-3 |
Description and Uses
In April 2011, the U.S. FDA approved vandetanib (ZD6474) for the treatment of symptomatic or progressive medullary thyroid cancer (MTC) in adult patients with inoperable advanced ormetastatic disease. Vandetanib inhibits KDR/VEGFR2, VEGFR3, EGFR, and RET kinases with IC50's of 40, 110, 500, and <100 nM, respectively. In athymic mice bearing MTC tumors, a 14.5-fold reduction of tumor volume was observed after 45 days of treatment with vandetanib at 50 mg/kg/day. The decrease in tumor volume was accompanied by decreases in mitotic index (Ki67) and tumor angiogenesis in treated xenografts. Key steps in the synthesis of vandetanib include the displacement of the chlorine atom from 7-benzyloxy-4-chloro-6-methoxyquinazoline with 4-bromo-2- fluoroaniline under acidic conditions in a protic solvent and a Mitsunobu reaction of a N-protected piperidine alcohol with a phenol.
Vandetanib is a broad spectrum, orally available kinase inhibitor that targets primarily tyrosine kinases, including vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR), with IC50 values in the nanomolar range. It also potently blocks non-receptor tyrosine kinases, including ABL, RET, and SRC, as well as several serine/threonine kinases. Primarily because of its effects on receptor tyrosine kinases like VEGFR and EGFR, vandetanib inhibits angiogenesis, cell growth, and metastasis and is effective against certain forms of cancer.[Cayman Chemical]
Safety
Symbol(GHS) | GHS05,GHS07,GHS09 |
Signal word | Danger |
Hazard statements | H302-H312-H315-H318-H332-H335-H227-H410 |
Precautionary statements | P210-P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P310-P330-P332+P313-P362-P370+P378-P403+P233-P403+P235-P405-P501-P273 |
Safety Statements | 24/25 |
HS Code | 29333220 |
Hazardous Substances Data | 443913-73-3(Hazardous Substances Data) |